← Oncology Approval Tracker

FDA DECISION ·

Breyanzi

lisocabtagene maraleucel · Juno Therapeutics (Bristol Myers Squibb)

FDA approvalNew or expanded indicationMarginal zone lymphoma
Open LinkedIn brief ↓

1 min read · estimated

Sources

APPROVED USE

What FDA approved

For adults with relapsed or refractory marginal zone lymphoma after at least two prior systemic treatment lines.

LAMPGEN ANALYSIS

Why it matters

The decision introduced the first FDA-approved CAR T-cell therapy for marginal zone lymphoma.

What research teams should watch

Refer to cellular therapy early enough to coordinate leukapheresis, manufacturing, bridging therapy when needed, and post-infusion monitoring.

PRIMARY RECORDS

Sources